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Introduction: A main drawback of neoadjuvant chemotherapy is
that it may increase operative morbidity and mortality. The aim of
this study was to determine the impact of chemotherapy on these
complications.
Methods: Patient data were collected from the Epithor database.
From June 2002 to June 2004, 3888 successive observations of
surgery for lung cancer have been reported from 51 thoracic surgery
departments throughout France. Logistic regression analysis was
performed to identify preoperative clinical characteristics of patients
with significant postoperative complications.
Results: Of 3888 patients, 555 (14.3%) received induction chemo-
therapy. The groups were similar with respect to sex and the number
of comorbidities. The in-hospital mortality rate was 3.01%. The
multivariate analysis allows us to identify age (older than 65 years),
sex (male), preoperative clinical score (moderate and severe), sur-
gical procedure (right pneumonectomy and bilobectomy) as signif-
icantly associated with in-hospital mortality. No statistical differ-
ence was observed according to the delivery or preoperative
chemotherapy. In total, 1219 patients (31.4%) had at least one
postoperative complication. Using a multivariate analysis, we ob-
served a significant correlation between morbidity and age (older
than 65 years), sex (male), presence of comorbidities (two or more),
clinical score (moderate), and type of operation (bilobectomy).
Preoperative administration of chemotherapy did not significantly
influenced postoperative morbidity.
Conclusions: Preoperative chemotherapy is not associated with an
increase in either the mortality rate or major surgical complications.
Future randomized trials are warranted to confirm the survival
benefit of this strategy.
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Neoadjuvant chemotherapy treatment for non-small celllung cancer (NSCLC) has been evaluated for many
years with promising results.1–5 The rationale for neoadjuvant
chemotherapy treatment is that, even in early-stage lung
cancer, there is a high incidence of disease recurrence after
surgery. Most recurrences are systemic, suggesting the pres-
ence of micrometastasis at the time of diagnosis. Delivering
chemotherapy before (neoadjuvant) or after (adjuvant) sur-
gery may eradicate micrometastasis.
Preoperative delivery of chemotherapy is an attractive
strategy compared with postoperative treatment because (1)
micrometastases are eradicated earlier, (2) performance status
is better preoperatively, (3) compliance with the treatment is
better, (4) clinical and pathological response can be easily
assessed, (5) downstaging the tumor can facilitate the surgery
in some cases.4 Neoadjuvant chemotherapy has been widely
used in early-stage lung cancer and is considered the standard
of care in selected patients with stage IIIa disease.
A main drawback of neoadjuvant chemotherapy is that
it may increase operative morbidity. Chemotherapy is known
to lead to neutropenia, to alter leukocyte bactericidal activity,
and to cause lung fibrosis.6 This may lead to an increased rate
of postoperative infectious complications or respiratory in-
sufficiency. Yet there is insufficient information on whether
neoadjuvant chemotherapy increases the risk of postoperative
complications.
Determining whether preoperative chemotherapy in-
creases the risk of postoperative complications is critical
information for lung cancer clinicians and patients. We set
out to compare the risk of postoperative complications in
patients who received neoadjuvant treatment with patients
who received no preoperative treatment using the multicenter
Epithor database, which includes data on more than 3700
patients with lung cancer who underwent surgical resection.
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PATIENTS AND METHODS
Patients
Patient data were collected from the Epithor database.
Epithor is a French electronic prospective database created in
2002 by the French Society of Thoracic and Cardiovascular
Surgery (CNIL registration number: 809833). From June
2002 to June 2004, 3888 successive observations of surgery
for lung cancer have been reported from 51 thoracic surgery
departments throughout France. Each department sent ano-
nymized files to the national databank. This databank was
created to generate an exhaustive patient registration for each
participating thoracic surgery department. At the time of
analysis, no external audit was performed. Nevertheless, this
database can also be used for registration of patients in
administrative hospital files and participation in this databank
is now mandatory to accredit surgery departments. We can
thus anticipate exhaustivity for this databank. The data col-
lected are patient characteristics (age, sex, weight, height,
anesthesia score [American Society of Anesthesia [ASA]
score), World Health Organization performance status (PS),
postoperative predictive forced expiratory volume in 1 sec-
ond (FEV1P) and comorbidities, as many as four per patient),
surgery-related factors (preoperative treatment, type of re-
moval, postoperative complications [as many as three per
patient], length of stay, date and cause of death). Some of
these items are mandatory to validate each patient’s file
(comorbidities, postoperative complications, and length of
stay). The comorbidities are only significant surgical comor-
bidities. Patients who received induction radiotherapy or
radiochemotherapy were excluded from this study because
they represent a small and heterogeneous group (n  89).
METHOD
The primary outcome variable was postoperative com-
plications (including death within the first month after sur-
gery). The analyzed predictor variables were patient charac-
teristics, tumor characteristics, and therapeutic procedures.
The preoperative status was evaluated by a three-level clini-
cal score integrating the ASA score, the PS, and the FEV1P
(Table 1).
Statistical Analysis
Data were analyzed using Stata Statistical Software:
Release 7.0 (Stata Corporation, College Station, TX). The
Pearson 2 test was used to compare categorical variables.
Logistic regression analysis was performed to identify pre-
operative clinical characteristics of patients who were signif-
icantly associated with postoperative complications. We used
the forward stepwise method with the significant variables
shown by the univariate analysis at the level of 20%. Inter-
actions were tested by the final model. Model stability was
tested. Changes were considered as statistically significant at
a level of p  0.05.
RESULTS
Using the search engine of the Epithor database, we
isolated 3888 patients from 51 institutions who were operated
on for NSCLC between 2002 and 2004. Patient data are listed
in Table 2. The pathological distribution was 44.3% for
adenocarcinoma, 37.5% for squamous cell carcinoma, 6.5%
for large cell carcinoma, and 11.7% for other less frequent
carcinomas.
A total of 555 (14.3%) patients received neoadjuvant
chemotherapy. Clinical characteristics of patients who re-
ceived preoperative chemotherapy and patients who did not
have any preoperative treatment are listed in Table 2. The
groups were similar with respect to sex and the number of
comorbidities. Statistically differences were observed for the
clinical score (more severe in the chemotherapy group), the
stage distribution (more advanced disease in the chemother-
apy group), and the surgical procedure (fewer pneumonecto-
mies in the surgery group).
Mortality
There were 117 deaths (3.01%) among the 3888 pa-
tients during the first month after surgery. The multivariate
analysis allows us to identify age (older than 65 years), sex
(male), preoperative clinical score (moderate and severe), and
surgical procedure (right pneumonectomy and bilobectomy)
as significantly associated with in-hospital mortality. Inter-
estingly, no statistical differences were observed according to
the delivery or preoperative chemotherapy as 20 deaths oc-
curred in the neoadjuvant chemotherapy group (3.6%) and 97
(2.9%) in the surgery group (p  0.38). The statistical
significance of the association between each factor that con-
tributes to the model of logistic regression and mortality
within the 30 days after surgery is reported in Table 3.
Morbidity
A total of 1219 patients (31.4%) had at least one
postoperative complication. In this series, the most frequent
postoperative complications were atelectasis (7.1%), pro-
longed air leak (6.8%), pneumonia (4.2%), arrhythmias
(3.4%), hemorrhage (2.2%), acute respiratory distress syn-
drome (1.8%), vocal cord paralysis (1.7%), and empyema
with or without fistula (1.1%). In total, 12.5% of the patients
who underwent surgery had an infectious postoperative com-
plication. Table 4 shows the univariate and multivariate
analyses of postoperative morbidity. Using a multivariate
analysis, we observed a significant correlation between mor-
bidity and age (older than 65 years), sex (male), presence of
comorbidities (two or more), clinical score (moderate), and
type of operation (bilobectomy). Neither preoperative che-
motherapy nor clinical stage had significant influence on
postoperative morbidity.









1–2 1 0–1 1 50% 1 Light 3
3 2 2 2 20%–50% 2 Moderate 4–6
4 3 3 3 20% 3 Severe 7–9
ASA, American Society of Anesthesia; WHO, World Health Organization; PS,
performance status; FEV1P, postoperative predictive forced expiratory volume in 1
second.
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DISCUSSION
Surgical resection is the primary treatment for pa-
tients with early stage NSCLC, but most of these patients
will have disease recurrence, two thirds of which are
distant recurrences.7–9 Addition of adjuvant systemic treat-
ment reduces the risk of disease recurrence and improves
mortality in patients with stage II and higher disease, as
demonstrated in international randomized studies.10–12 It is
unclear whether neoadjuvant treatment has similar or greater
benefit. Preoperative administration has also been shown to
increase survival in two older trials1,2 but failed to show
significant advantage on survival in a larger French trial.3A
recent meta-analysis concluded that adjuvant chemotherapy
is a standard treatment in resected NSCLC, whereas more
data are needed to confirm such a role for induction chemo-
therapy beyond stage IIIa patients.13
Advantages of induction treatment are better chemo-
therapy tolerance, less toxicity, the possibility to assess che-
mosensitivity, earlier treatment of micrometastasis, and de-
livery of chemotherapy in unaltered vessels.4 Conversely,
there may be a higher rate of surgical complications and
mortality. Chemotherapy is known to induce neutropenia, but
because a surgical procedure is performed at least 4 weeks
after the last course, leukocyte counts are usually normalized.
Nevertheless, chemotherapy can also induce a prolonged
alteration of leukocyte functional properties, thus increasing
the risk of infection.6 It has also been reported that chemo-
therapy might alter the alveolocapillary membrane. Leo et
al.14 showed that three cycles of a combination of cisplatinum
and gemcitabine impair the alveolocapillary diffusion of
carbon monoxide (DLCO). Moreover, some chemotherapy
regimens are known to induce specific lung toxicity, such as
fibrosis with mitomycin,15 that may lead to postoperative
complications.16 In our study details about chemotherapy
regimens were not individually available, but we can antici-
pate that most patients received cisplatinum-based chemo-
therapy without mitomycin for induction chemotherapy.
In our series, we did not observe any significant impact
of preoperative chemotherapy on the mortality rate. The
30-day mortality rate (3.01%) was similar to those in pub-
lished data (1.3%–3.7%).17–20 The consequences of preoper-
ative chemotherapy have already been investigated by other
authors.3,21–23 Depierre et al.3 found that the total number of
treatment-related deaths after surgery was 16 in the chemo-
therapy (mitomycin, ifosfamide, cisplatin) arm and nine in
the surgery arm, but the difference was not significant (p 
0.16). Martin et al.21 found a total mortality of 2.4% and
11.3% for all lobectomies and pneumonectomies, respec-
tively, but mortality was 11 of 46 (23.9%) for right pneumo-
nectomy. In a monocentric study, Siegenthaler et al.22 did not
observe a higher mortality rate when chemotherapy was per-
formed before surgery compared with surgery alone. Veronesi et





n 555 3333 3888
Age, yr, mean 59.5 62.5 62.18 0.05
Sex, % 18.1 F/81.9 M 20.7 F/79.3 M 20.7 F/79.3 M ns
Clinical score,a n (%) 0.05
Light 271 (48.9) 1828 (55.6) 2099 (54.6)
Moderate 266 (48.0) 1408 (42.8) 1674 (43.6)
Severe 17 (3.1) 51 (1.6) 68 (1.8)
Comorbidities, n (%) ns
0 122 (22.0) 688 (20.6) 810 (20.8)
1 184 (33.2) 1058 (31.7) 1242 (31.9)
2–4 249 (44.9) 1587 (47.6) 1836 (47.2)
Postoperative stage, n (%) 0.05
IA 42 (9.0) 480 (19.0) 522 (17.5)
IB 73 (15.6) 728 (28.8) 801 (26.8)
IIA 11 (2.4) 59 (2.3) 70 (2.3)
IIB 80 (17.1) 407 (16.1) 487 (16.3)
IIIA 140 (30.0) 454 (18.0) 594 (19.9)
IIIB 74 (15.9) 218 (8.6) 292 (9.8)
IV 47 (10.1) 178 (7.1) 225 (7.5)
Surgery, n (%) 0.05
Lobectomy 264 (47.6) 2097 (62.9) 2361 (60.7)
Pneumonectomy 195 (35.1) 506 (15.2) 701 (18.0)
Bilobectomy 37 (6.7) 171 (5.1) 208 (5.4)
Otherb 59 (10.6) 559 (16.8) 618 (15.9)
ns, not significant.
a Clinical score is defined in Table 1.
b Other corresponds with wedge resection or combined resection.
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al.23 proposed that a parenchyma-sparing resection might be a
valid option for selected patients with locally advanced lung
cancer after induction treatment. It seems from several studies
that right pneumonectomy is associated with a higher rate of
mortality, as high as 24%.24 In our work, the mortality of right
pneumonectomy was surprisingly lower in the induction che-
motherapy group (5.6% versus 9.6%, p  0.05), although this
may have occurred by chance alone. These results should be
interpreted with caution as the two groups are not well balanced
(Table 2) because patients from the chemotherapy group are
younger and have more advanced disease. These differences and
variability might also be explained by the small number of
patients in the induction arms.
We also found that preoperative treatment did not
increase the rate of surgical complications. In our multivari-
TABLE 3. Univariate and Multivariate Analysis of Mortality







% of Death OR aOR 95% CI
Neoadjuvant TTT (n  3888)
Noref 2.9 0.0 — —
Yes 3.6 1.2 — —
p 0.38a ns
Age, yr (n  3841)
64ref 2.0 1.0 1.0 —
65–74 3.8 2.0 2.1 1.3–3.4
75 5.4 2.8 2.7 1.6–4.6
p 0.001a 0.001b
Sex (n  3885)
Menref 3.5 1.0 1.0 —
Women 1.1 0.3 0.3 0.1–0.7
p 0.001a 0.001b
Comorbidity (n  3888)
0ref 1.2 1.0 — —
1 3.0 2.5 — —
2–4 3.8 3.2 — —
p 0.001a ns
Clinical status (n  3841)
Slightref 1.9 1.0 1.0 —
Moderate 3.9 2.2 2.1 1.3–3.2
Severe 13.2 8.1 4.8 2.0–11.9
p 0.001a 0.001b
Surgery (n 3888)
Lobectomyref 2.0 1.0 1.0 —
Left pneumonectomy. 3.5 1.7 1.5 0.8–2.9
Bilobectomy 7.2 3.7 3.3 1.7–6.3
Right pneumonectomy 8.5 4.4 3.8 2.2–6.6
Other 2.4 1.2 1.0 0.5–2.0
p 0.001a 0.0001b
Clinical stage (n  2991)
pTNM Iref 2.7 1.0 — —
pTNM II 4.9 1.9 — —
pTNM III 4.7 1.8 — —
pTNM IV 2.7 1.0 — —
p 0.02a ns
TTT, treatment; OR, odds ratio; aOR, OR adjusted for the other factor; CI,
confidence interval of aOR; ref, reference category; ns, not significant.
a Chi-square test.
b Likelihood ratio.







% of Complications OR aOR 95% CI
Neoadjuvant TTT
(n  3888)
Noref 31.4 0.0 — —
Yes 33.0 1.1 — —
p 0.47a ns
Age, yr (n  3841)
64ref 28.2 1.0 1.0 —
65–74 35.2 1.4 1.3 1.1–1.5
75 37.8 1.5 1.5 1.2–1.8
p 0.001a 0.01b
Sex (n  3885)
Menref 34.4 1.0 1.0 —




0ref 24.7 1.0 1.0 —
1 28.5 1.2 1.0 0.8–1.3




Slightref 27.9 1.0 1.0 —
Moderate 36.1 1.5 1.4 1.2–1.6
Severe 44.1 2.0 1.5 0.9–2.5
p 0.001a 0.001b
Surgery (n  3888)
Lobectomyref 33.3 1.0 1.0 —
Left
pneumonectomy
35.8 1.1 1.1 0.8–1.4
Bilobectomy 42.8 1.5 1.3 1.0–1.8
Right
pneumonectomy
32.1 0.9 0.9 0.7–1.2




pTNM Iref 33.3 1.0 — —
pTNM II 36.5 1.1 — —
pTNM III 38.1 1.2 — —
pTNM IV 30.4 0.9 — —
p 0.03a ns
OR, odds ratio; aOR, OR adjusted for the other factor; CI, confidence interval of
aOR; ref, reference category.
a Chi-square test.
b Likelihood ratio.
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ate analysis, only age, sex, number of comorbidities, clinical
score, and surgical procedure had an impact on the occur-
rence of complications. At least one complication was ob-
served in 31.4% of patients who underwent surgery, a per-
centage that is similar to data reported in other surgical series
(17%–65%).3,21–23,25,26 The impact of induction chemother-
apy on surgical complications has been studied and is still
debated. For example, Roberts et al.27 reported a highly
significant increase of complications after three courses of
preoperative carboplatin-paclitaxel chemotherapy. In their
work, 34 patients who received chemotherapy before surgery
were compared with 67 treated with surgery alone. Striking
increases were found in the incidence of life-threatening
complications (26.5% versus 6.0%, p  0.0036), major
complications (47.1% versus 19.4%, p  0.0037), reintuba-
tion (17.6% versus 3.0%, p  0.0093), and tracheostomy
(11.8% versus 0%, p  0.0042) in those patients who re-
ceived preoperative chemotherapy. Most of the published
series did not show any increase in complications.3,22,23,25 For
example, Depierre et al.3 found in their randomized phase III
trial that there was a nonsignificant excess of morbidity in the
preoperative chemotherapy arm during the 30 postoperative
days. In our study, 12.5% of patients had infectious compli-
cations (14.6% in the chemotherapy group versus 12.1% in
the surgery group, p  0.05).
Univariate analysis did not show any difference either
concerning atelectasis, prolonged air leak, pneumonia, ar-
rhythmias, hemorrhage, acute respiratory distress syndrome,
or vocal cord paralysis. The only significant difference ob-
served was a higher risk of bronchial fistula with or without
empyema (2.6% versus 0.9%, p  0.05) and the length of
stay was 1 day longer in the chemotherapy group (p 
0.0009). This might be explained by the highest number of
pneumonectomy (16% versus 6.2%), more advanced stages,
and highest clinical score (48.1% versus 42.9%) in this latter
group. We can also hypothesize that for such patients sur-
geons are more likely to propose protection of the bronchial
stump procedure. In the particular case of right pneumonec-
tomy (n  296, 89 of which were performed after induction
chemotherapy), we observed a higher risk of complications
(36% versus 29%), of acute respiratory distress syndrome
(6.7% versus 4.8%), and of fistulae (9% versus 4.4%), but
these differences were not statistically significant. The occur-
rence of acute respiratory distress syndrome might be ex-
plained by impairment of lung diffusion after chemotherapy,
as proposed by Leo et al.,14 and it is suggested that follow-up
of DLCO should be done and pneumonectomy avoided if
DLCO measurement decreases by more than 15% after che-
motherapy.
CONCLUSION
Preoperative chemotherapy is not associated with an
increase in either mortality rate or major surgical complica-
tions. We think that the combination of preoperative chemo-
therapy and surgery might even be safer and more effective
with the use of new chemotherapy regimens and improve-
ments in surgical procedure. Induction chemotherapy appears
to be a safe procedure. Future randomized trials are warranted
to confirm the survival benefit of this strategy.
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